FDA warns hydroxychloroquine may weaken effectiveness of cor
Now open: Certificate Course in Management of Covid-19 by Govt. Of Gujarat and PlexusMDKnow more...Now open: Certificate Course in Management of Covid-19 by Govt. Of Gujarat and PlexusMDKnow more...
Get authentic, real-time news that helps you fight COVID-19 better.
Install PlexusMD App for doctors. It's free.
U.S. Food and Drug Administration on 15 June, issued a warning for health care providers about the investigational antiviral drug remdesivir, which has received EUA for the treatment of COVID-19 patients with severe disease.

• The Food and Drug Administration warned Monday that Covid-19 patients taking anti-malaria drug hydroxychloroquine along with antiviral drug remdesivir may weaken the effectiveness of the latter.

• The FDA is revising its fact sheet for health-care providers that accompanies remdesivir to state “that co-administration of remdesivir and chloroquine phosphate or hydroxychloroquine sulfate is not recommended as it may result in reduced antiviral activity of remdesivir.”

• A recently completed nonclinical study discovered the potential drug interaction, the agency said in its notice published 15 June evening.

• “The agency is not aware of instances of this reduced activity occurring in the clinical setting but is continuing to evaluate all data related to remdesivir,” the FDA wrote.

• Hydroxychloroquine had also been granted an EUA for the coronavirus, but the designation was revoked earlier 15 June after the FDA found it was unlikely to be effective.

Source: https://www.fda.gov/news-events/press-announcements/coronavirus-covid-19-update-fda-warns-newly-discovered-potential-drug-interaction-may-reduce
S●●●●●t G●●i and 7 others like this3 shares
Like
Comment
Share